Yuexin Yu
Director at Andera Partners
Paris, Île-de-France
Overview
Work Experience
Director
2024 - Current
Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED, JenaValve
Investment Director
2021 - 2024
Board Member
2024
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
Raised $268,000,000.00 from NEXTBio Capital, RTW Investments, Longwood Fund, RA Capital Management, Sectoral Asset Management, Marshall Wace, Avego Bioscience Capital, SymBiosis, FemHealth Ventures and Andera Partners.
Board Observer
2022
JenaValve is a medical device company focused on the design and development of innovative transcatheter heart valve solutions
Raised $341,567,865.00 from Valiance Asset Management, Qatar Investment Authority, Bain Capital Life Sciences, Venture Incubator, Andera Partners, Cormorant Asset Management, RMM, Innovatus Capital Partners, Peijia Medical and Gimv.
Board Observer
2022
Vice President
2020 - 2021
InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), CanSino (HK.6185), EdiGen, RareStone Group, Imperative Care, HeMo Bioengineering
Senior Associate
2018 - 2020
Associate
2016 - 2018
Project Manager
2014 - 2016
Remicade, Keytruda
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Business Development Associate
2013 - 2013
Biotheranostics is a commercial-stage molecular diagnostics company that support physicians in the treatment of cancer patients.
Raised $32,000,000.00 from HealthQuest Capital, Evidity Health Capital and MVM Life Science Partners.
Business Analyst
2012 - 2013
Education
Bachelor of Pharmacy
2007 - 2011
Grande Ecole
2011 - 2013